You are here: Industry Insights > chronic lymphocytic leukemia

News List

Calquence Approved in EU for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
November 18, 2020
AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukemia (CLL), the most common type of leukemia in ..
FDA Approves IMBRUVICA, Rituximab Combination for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
April 24, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for ...
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017 drugs
December 27, 2019
For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia & Lymphoma.
ASH: Johnson & Johnson, AbbVie's Imbruvica steals the CLL spotlight with phase 3 study wins fiercepharma
December 05, 2018
Johnson & Johnson and AbbVie’s Imbruvica already competes in previously untreated chronic lymphocytic leukemia (CLL). But with a new lineup of head-to-head data, the partners are looking to own it.